Medionko-Institut GbR

Industry / private company


Location: Berlin, Germany (DE) DE

ISNI: -

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial (2025) Villacampa G, Llop-Guevara A, Filmann N, Herencia-Ropero A, Fasching P, Karn T, Marmé F, et al. Journal article Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2024) Meyer-Wilmes P, Huober J, Untch M, Blohmer JU, Janni W, Denkert C, Klare P, et al. Journal article Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy (2021) Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, et al. Journal article Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332) (2020) Hauke J, Ernst C, Fasching P, Jackisch C, Seither F, Klare P, Rhiem KE, et al. Conference contribution Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) (2020) Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, et al. Journal article